In 86 pretreated cancer patients with mismatch repair deficiency, researchers saw objective response rates exceeding 50 percent after anti-PD-1 immunotherapy.
Qiagen will use NGS to develop gene expression profiles related to BMS immuno-oncology therapies; and the company has licensed IO therapy response biomarkers from JHU.
Researchers used exome and targeted sequencing to find alterations affecting KRAS and other cancer driver genes in a subset of deep infiltrating endometriosis samples.
Johns Hopkins University researchers have developed a method called targeted error correction sequencing, or TEC-Seq, to increase liquid biopsy sensitivity.
Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
